Flecainide

Evidence Level: L3

Predicted Indications: 9

Flecainide

Pharmacist Assessment Report

Flecainide: From Atrial Fibrillation to Stroke Disorder

One-Sentence Summary

Flecainide is a class 1C sodium channel blocker originally used for rhythm control in atrial fibrillation. The TxGNN model predicts it may be relevant to stroke disorder, but the support is indirect: 1 clinical trial (with an arrhythmia endpoint, not a stroke endpoint) and 20 publications, mostly about atrial fibrillation rather than stroke itself.

Quick Overview

Item	Content
Original Indication	Atrial fibrillation
Predicted New Indication	Stroke disorder
TxGNN Prediction Score	0.9991
Evidence Level	L3
Canada Market Status	Marketed (marketed DINs: 10 of 10)
Number of DINs	10 (marketed: 10)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, flecainide is a class 1C antiarrhythmic that blocks sodium channels, and its efficacy in maintaining or restoring normal rhythm in atrial fibrillation is established.

The link to stroke is indirect. Atrial fibrillation is a major cause of cardioembolic stroke, so keeping the heart in sinus rhythm may lower arrhythmia-related stroke risk. No study provided shows that flecainide directly reduces stroke.

There is an important limitation. Class 1C agents are contraindicated in structural or ischaemic heart disease, which describes many stroke patients. This restricts how widely the drug could be applied.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05213104	Phase 3	Active, not recruiting	186	Tests flecainide to lower the risk of atrial arrhythmia or tachycardia after patent foramen ovale (PFO) closure, a stroke-prevention setting. The primary endpoint is arrhythmia, not stroke recurrence. Results are not yet available.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38702961	2024	RCT (secondary analysis)	Europace	Safety and efficacy of long-term sodium channel blocker (flecainide, propafenone) early rhythm control in EAST-AFNET 4
25820938	2015	Systematic review	Cochrane Database Syst Rev	Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
38551548	2024	Cohort/Review	JACC Clin Electrophysiol	Class 1C antiarrhythmics for PVC suppression in nonischaemic cardiomyopathy with ICDs
41954064	2026	Cohort	J Am Heart Assoc	Long-term outcomes with class 1C antiarrhythmic use in atrial fibrillation
41152878	2025	Cohort	BMC Med	Concomitant DOAC and interacting antiarrhythmic use and risk of stroke and bleeding in non-valvular AF
37109225	2023	Randomised pilot study	J Clin Med	Carvedilol vs flecainide for idiopathic outflow tract PVCs
8729366	1995	Clinical study	Arch Mal Coeur Vaiss	Atrial electrophysiological study with IV flecainide in 38 patients with unexplained ischaemic cerebrovascular events
25430048	2014	Review	BMJ Clin Evid	Acute-onset atrial fibrillation; notes increased stroke and heart failure risk
19265095	2009	Review	Chest	Acute management of atrial fibrillation, rate vs rhythm control
27884575	2017	Case report	J Emerg Med	Brugada pattern caused by flecainide overdose

Most of this literature concerns atrial fibrillation and flecainide safety. None demonstrates that flecainide treats or prevents stroke.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02534819	FLECAINIDE	Not specified	Not specified
02275538	APO-FLECAINIDE	Not specified	Not specified
02459957	AURO-FLECAINIDE	Not specified	Not specified
02493713	JAMP FLECAINIDE	Not specified	Not specified
02516063	AG-FLECAINIDE	Not specified	Not specified

Ten valid single-ingredient licences are listed in total; the five above are shown.

Safety Considerations

Contraindications flagged in the knowledge graph (drug-disease contraindication links, not package insert text): kidney disease, liver disease, gallbladder disease, potassium deficiency, myocardial infarction, coronary thrombosis, haemoglobinopathy, atrioventricular block, sick sinus syndrome (including the familial form), and pyoureter.
Drug interactions: 100 interactions were identified. Major interactions include dolasetron and eliglustat. Moderate interactions include famotidine, cimetidine, loperamide, bupropion, clarithromycin, levofloxacin, lorcaserin, palonosetron, trospium and several laxatives or bowel preparations. Minor interactions include ascorbic acid, potassium citrate and metronidazole.
Safety signals from the literature: proarrhythmia, particularly in structural or ischaemic heart disease; overdose toxicity, including unmasking of a Brugada pattern; and the need for co-management with anticoagulants in AF patients.

Please refer to the package insert for the full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The only trial measures arrhythmia after PFO closure rather than stroke, and no study shows that flecainide reduces stroke. The pathway runs indirectly through AF rhythm control. In addition, the contraindication in structural and ischaemic heart disease, which is common in stroke patients, limits real-world applicability. Evidence stands at L3 and the item is best treated as a research question.

To proceed, the following is needed:

Results from NCT05213104, and ideally a trial with stroke or cerebrovascular events as the endpoint
Mechanism of action data
Package insert warnings and contraindications from Health Canada, which are currently missing and block safety screening
A defined target population (for example, patients with AF and no structural heart disease) with an anticoagulation co-management plan
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.